acsbrightedge.org ↗Activity from announced rounds
American Cancer Society BrightEdge invests in cancer-focused innovation and uses financial returns to support the society’s wider mission.
BrightEdge is the innovation and impact-investment arm of the American Cancer Society. It brings the organisation’s cancer research and patient-support experience to businesses developing scalable responses to unmet needs, combining financial investment with strategic support.
The RoundOS financing history includes CellCentric, TippingPoint Biosciences and Cloverleaf Bio. Cloverleaf’s issuer announcement identifies BrightEdge in its RNA-therapeutics seed syndicate, while CellCentric describes BrightEdge’s backing of its cancer-drug development. These are selected company financings captured here.
Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer